@article{MTMT:31460314,
	title = {EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update},
	url = {https://m2.mtmt.hu/api/publication/31460314},
	author = {Gossec, Laure and Baraliakos, Xenofon and Kerschbaumer, Andreas and de Wit, Maarten and McInnes, Iain and Dougados, Maxime and Primdahl, Jette and McGonagle, Dennis G. and Aletaha, Daniel and Balanescu, Andra and Bálint, Péter Vince and Bertheussen, Heidi and Boehncke, Wolf-Henning and Burmester, Gerd R. and Canete, Juan D. and Damjanov, Nemanja S. and Kragstrup, Tue Wenzel and Kvien, Tore K. and Landewe, Robert B. M. and Lories, Rik Jozef Urbain and Marzo-Ortega, Helena and Poddubnyy, Denis and Rodrigues Manica, Santiago Andres and Schett, Georg and Veale, Douglas J. and Van den Bosch, Filip E. and van der Heijde, Desiree and Smolen, Josef S.},
	doi = {10.1136/annrheumdis-2020-217159},
	journal-iso = {ANN RHEUM DIS},
	journal = {ANNALS OF THE RHEUMATIC DISEASES},
	volume = {79},
	unique-id = {31460314},
	issn = {0003-4967},
	abstract = {Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA).Methods According to the EULAR standardised operating procedures, a systematic literature review was followed by a consensus meeting to develop this update involving 28 international taskforce members in May 2019. Levels of evidence and strengths of recommendations were determined.Results The updated recommendations comprise 6 overarching principles and 12 recommendations. The overarching principles address the nature of PsA and diversity of both musculoskeletal and non-musculoskeletal manifestations; the need for collaborative management and shared decision-making is highlighted. The recommendations provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs and local glucocorticoid injections are proposed as initial therapy; for patients with arthritis and poor prognostic factors, such as polyarthritis or monoarthritis/oligoarthritis accompanied by factors such as dactylitis or joint damage, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drugs (bDMARDs) targeting tumour necrosis factor (TNF), interleukin (IL)-17A or IL-12/23 should be initiated, taking into account skin involvement if relevant. If axial disease predominates, a TNF inhibitor or IL-17A inhibitor should be started as first-line disease-modifying antirheumatic drug. Use of Janus kinase inhibitors is addressed primarily after bDMARD failure. Phosphodiesterase-4 inhibition is proposed for patients in whom these other drugs are inappropriate, generally in the context of mild disease. Drug switches and tapering in sustained remission are addressed.Conclusion These recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.},
	year = {2020},
	eissn = {1468-2060},
	pages = {700-712},
	orcid-numbers = {Gossec, Laure/0000-0002-4528-310X; de Wit, Maarten/0000-0002-8428-6354; Primdahl, Jette/0000-0002-1049-4150; Kragstrup, Tue Wenzel/0000-0002-6439-397X}
}

@article{MTMT:31173212,
	title = {EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update},
	url = {https://m2.mtmt.hu/api/publication/31173212},
	author = {Smolen, Josef S and Landewé, Robert B M and Bijlsma, Johannes W J and Burmester, Gerd R and Dougados, Maxime and Kerschbaumer, Andreas and McInnes, Iain B and Sepriano, Alexandre and van Vollenhoven, Ronald F and de Wit, Maarten and Aletaha, Daniel and Aringer, Martin and Askling, John and Balsa, Alejandro and Boers, Maarten and den Broeder, Alfons A and Buch, Maya H and Buttgereit, Frank and Caporali, Roberto and Cardiel, Mario Humberto and De Cock, Diederik and Codreanu, Catalin and Cutolo, Maurizio and Edwards, Christopher John and van Eijk-Hustings, Yvonne and Emery, Paul and Finckh, Axel and Gossec, Laure and Gottenberg, Jacques-Eric and Hetland, Merete Lund and Huizinga, Tom W J and Koloumas, Marios and Li, Zhanguo and Mariette, Xavier and Müller-Ladner, Ulf and Mysler, Eduardo F and da Silva, Jose A P and Poór, Gyula and Pope, Janet E and Rubbert-Roth, Andrea and Ruyssen-Witrand, Adeline and Saag, Kenneth G and Strangfeld, Anja and Takeuchi, Tsutomu and Voshaar, Marieke and Westhovens, René and van der Heijde, Désirée},
	doi = {10.1136/annrheumdis-2019-216655},
	journal-iso = {ANN RHEUM DIS},
	journal = {ANNALS OF THE RHEUMATIC DISEASES},
	volume = {79},
	unique-id = {31173212},
	issn = {0003-4967},
	year = {2020},
	eissn = {1468-2060},
	pages = {685-699},
	orcid-numbers = {Poór, Gyula/0000-0001-9235-3900}
}

@article{MTMT:3201245,
	title = {2016 update of the EULAR recommendations for the management of early arthritis},
	url = {https://m2.mtmt.hu/api/publication/3201245},
	author = {Combe, Bernard and Landewé, Robert and Daien, Claire I and Hua, Charlotte and Aletaha, Daniel and Álvaro-Gracia, Jose María and Bakkers, Margôt and Brodin, Nina and Burmester, Gerd R and Codreanu, Catalin and Conway, Richard and Dougados, Maxime and Emery, Paul and Ferraccioli, Gianfranco and Fonseca, Joao and Raza, Karim and Silva-Fernández, Lucía and Smolen, Josef S and Skingle, Diana and Szekanecz, Zoltán and Kvien, Tore K and van der Helm-van Mil, Annette and van Vollenhoven, Ronald},
	doi = {10.1136/annrheumdis-2016-210602},
	journal-iso = {ANN RHEUM DIS},
	journal = {ANNALS OF THE RHEUMATIC DISEASES},
	volume = {76},
	unique-id = {3201245},
	issn = {0003-4967},
	abstract = {Objectives Since the 2007 recommendations for the management of early arthritis have been presented, considerable research has been published in the field of early arthritis, mandating an update of the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.Methods In accordance with the 2014 EULAR Standardised Operating Procedures, the expert committee pursued an approach that was based on evidence in the literature and on expert opinion. The committee involved 20 rheumatologists, 2 patients and 1 healthcare professional representing 12 European countries. The group defined the focus of the expert committee and target population, formulated a definition of ♭management' and selected the research questions. A systematic literature research (SLR) was performed by two fellows with the help of a skilled librarian. A set of draft recommendations was proposed on the basis of the research questions and the results of the SLR. For each recommendation, the categories of evidence were identified, the strength of recommendations was derived and the level of agreement was determined through a voting process.Results The updated recommendations comprise 3 overarching principles and 12 recommendations for managing early arthritis. The selected statements involve the recognition of arthritis, referral, diagnosis, prognostication, treatment (information, education, pharmacological and non-pharmacological interventions), monitoring and strategy. Eighteen items were identified as relevant for future research.Conclusions These recommendations provide rheumatologists, general practitioners, healthcare professionals, patients and other stakeholders with an updated EULAR consensus on the entire management of early arthritis.},
	year = {2017},
	eissn = {1468-2060},
	pages = {948-959}
}